J&J's Spravato's Star Power Rises While Zytiga's Sets
Executive Summary
With Spravato's launch underway, J&J reports that 800 sites have been certified to administer the depression drug. Newer drugs drove pharma sales in the first quarter, while US sales of Zytiga declined 55% due to generic competition.
You may also be interested in...
J&J US Pharma Sales Under Pressure From Pricing And Generics
A 6% negative pricing impact in the US and generic Zytiga were headwinds for Johnson & Johnson's pharmaceutical business in the second quarter.
Novartis Settles Short-Lived Suit Over Janssen's Psoriasis Drug Promo
The companies resolve litigation as competition in the psoriasis drug market intensifies; there are now 12 approved products in the US, with TNF-alpha inhibitors still dominating.
Novartis Settles Short-Lived Suit Over Janssen's Psoriasis Drug Promo
Companies resolve litigation as competition in the psoriasis drug market intensifies; there are now 12 approved products in the US, with TNF-alpha inhibitors still dominating.